Plain-English translation of NCT06909682 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing whether a small wearable device called EmbracePlus, combined with artificial intelligence, can better monitor chronic heart failure patients and catch problems before they become serious. The device tracks vital signs like oxygen levels, heart rate, temperature, and sleep, and sends alerts if something concerning appears. The study compares people who use this device with people receiving standard heart failure care over six months.
Many heart failure patients only see their doctor every few months, which means dangerous changes can happen between visits without being caught. This study aims to see if continuous remote monitoring through wearable technology can spot problems early enough to prevent emergency hospital visits.
You likely qualify if…
You likely don't qualify if…
If you are assigned to the device group, you will wear the EmbracePlus wearable on your wrist for six months—it continuously tracks your heart and health signals and sends the information to a secure computer system. An artificial intelligence program watches for warning signs and alerts your doctors if something needs attention, which may lead to a video visit with your doctor or an in-person appointment. If you are in the standard care group, you will have regular check-up visits every three months as usual. Either way, the study lasts six months.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
Italy